EXELIXIS, INC.
EXELNasdaq
$55.92
↑ +0.4%Jul 17 close · end-of-day
Price
1Y↑ +24.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$14.9B
Enterprise Value
$14.2B
P/E
18.5
P/S
6.3
P/B
7.7
EV/EBITDA
14.7
PEG
0.3
FCF Yield
6.1%
Dividend Yield
—
Revenue (TTM)
$2.4B
Net Income (TTM)
$833.5M
Free Cash Flow (TTM)
$917.7M
Gross Margin
—
Operating Margin
39.4%
Net Margin
35.1%
ROE
43.1%
ROIC
63.9%
Debt / Equity
—
Net Cash
$777.2M
Return 1Y
+24.6%
Company profile
Exelixis, Inc. focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. Its products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma.
- CEO
- Michael M. Morrissey
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 1,220
- Headquarters
- California
- Website
- exelixis.com
Management & directors
- Aftab DanaEVP, Research and Development
- Haley Patrick J.EVP, Commercial
- Hefti BrendaSVP and General Counsel
- Morrissey MichaelPresident and CEO
- Senner Christopher J.EVP and CFO
Roles derived from SEC Form 4 filings.
Earnings
EXEL Q1 2026 Earnings
Period ends 2026-04-03
MetricActualYoY
Revenue$610.8M↑ +10.0%
Diluted EPS$0.79↑ +43.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2021 | FY2022 | FY2023 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
| Revenue | $987.5M | $1.4B | $1.6B | $1.8B | $2.2B | $2.3B |
| Gross profit | — | — | — | — | — | — |
| Operating income | $110.1M | $286.7M | $201.5M | $170.9M | $604.6M | $872.2M |
| Net income | $111.8M | $231.1M | $182.3M | $207.8M | $521.3M | $782.6M |
| Diluted EPS | $0.35 | $0.72 | $0.56 | $0.65 | $1.76 | $2.78 |
| Operating cash flow | $209.0M | $400.8M | $362.6M | $333.3M | $700.0M | $884.3M |
| Free cash flow | $178.6M | $346.6M | $334.9M | $292.9M | $671.5M | $875.8M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | 11.1% | 20.0% | 12.5% | 9.3% | 27.9% | 37.6% |
| Net margin | 11.3% | 16.1% | 11.3% | 11.4% | 24.0% | 33.7% |
| Line item | Q2 '24 | Q3 '24 | Q4 '25 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '26 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $637.2M | $539.5M | $566.8M | $555.4M | $568.3M | $597.8M | $598.7M | $610.8M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $275.9M | $136.1M | $163.2M | $186.9M | $213.6M | $236.5M | $235.2M | $251.3M |
| Net income | $226.1M | $118.0M | $139.9M | $159.6M | $184.8M | $193.6M | $244.6M | $210.5M |
| Diluted EPS | $0.77 | $0.40 | $0.47 | $0.55 | $0.65 | $0.69 | $0.89 | $0.79 |
| Operating cash flow | $119.5M | $271.3M | $240.3M | $211.4M | $49.0M | $290.3M | $333.5M | $251.8M |
| Free cash flow | $113.0M | $263.1M | $236.3M | $208.5M | $46.2M | $288.8M | $332.4M | $250.3M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 43.3% | 25.2% | 28.8% | 33.6% | 37.6% | 39.6% | 39.3% | 41.1% |
| Net margin | 35.5% | 21.9% | 24.7% | 28.7% | 32.5% | 32.4% | 40.9% | 34.5% |
Company news
Jul 16, 2026
Jul 11, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-01 | Eckhardt Sue Gail | Sale | 9,812 | $50.14 | $491,973.68 | filing |
| 2026-06-01 | WYSZOMIERSKI JACK L | Sale | 3,925 | $50.55 | $198,408.75 | filing |
| 2026-05-27 | Heyman Tomas J. | Award | 8,367 | $0.00 | $0.00 | filing |
| 2026-05-27 | Eckhardt Sue Gail | Award | 8,367 | $0.00 | $0.00 | filing |
| 2026-05-27 | Smith Julie | Award | 8,367 | $0.00 | $0.00 | filing |
| 2026-05-27 | Freire Maria C | Award | 8,367 | $0.00 | $0.00 | filing |
| 2026-05-27 | Oliver Bob | Award | 8,367 | $0.00 | $0.00 | filing |
| 2026-05-27 | WYSZOMIERSKI JACK L | Award | 8,367 | $0.00 | $0.00 | filing |
| 2026-05-27 | POSTE GEORGE | Award | 8,367 | $0.00 | $0.00 | filing |
| 2026-05-27 | Beckerle Mary C | Award | 8,367 | $0.00 | $0.00 | filing |
| 2026-05-27 | PAPADOPOULOS STELIOS | Award | 8,367 | $0.00 | $0.00 | filing |
| 2026-05-26 | Aftab Dana· EVP, Research and Development | Sale | 43,451 | $50.35 | $2.2M | filing |
| 2026-05-20 | Haley Patrick J.· EVP, Commercial | Sale | 32,110 | $49.81 | $1.6M | filing |
| 2026-05-18 | Senner Christopher J.· EVP and CFO | Sale | 34,901 | $50.00 | $1.7M | filing |
| 2026-05-18 | Hefti Brenda· SVP and General Counsel | Sale | 6,625 | $50.21 | $332,641.25 | filing |
| 2026-05-18 | MORRISSEY MICHAEL· President and CEO | Gift | 124,047 | $0.00 | $0.00 | filing |
| 2026-05-18 | MORRISSEY MICHAEL· President and CEO | Gift | 124,047 | $0.00 | $0.00 | filing |
| 2026-05-15 | MORRISSEY MICHAEL· President and CEO | Tax withholding | 128,497 | $51.10 | $6.6M | filing |
| 2026-05-15 | Senner Christopher J.· EVP and CFO | Tax withholding | 40,892 | $51.10 | $2.1M | filing |
| 2026-05-15 | Haley Patrick J.· EVP, Commercial | Tax withholding | 33,265 | $51.10 | $1.7M | filing |
| 2026-05-15 | Aftab Dana· EVP, Research and Development | Tax withholding | 30,578 | $51.10 | $1.6M | filing |
| 2026-05-15 | Hefti Brenda· SVP and General Counsel | Tax withholding | 6,411 | $51.10 | $327,602.10 | filing |
| 2026-05-07 | POSTE GEORGE | Sale | 60,000 | $45.71 | $2.7M | filing |
| 2026-05-07 | Freire Maria C | Sale | 20,634 | $46.00 | $949,164.00 | filing |
| 2026-05-07 | Freire Maria C | Option exercise | 20,634 | $19.77 | $407,934.18 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.